BGI
IOVA icon

B Group Inc’s Iovance Biotherapeutics IOVA Stock Holding History

B Group Inc’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.24M Hold
1,500,000
– – 2.93% 12
2026
Q1 		$5.26M Hold
1,500,000
– – 3.9% 9
2025
Q4 		$4.09M Hold
1,500,000
– – 3.02% 10
2025
Q3 		$3.25M Hold
1,500,000
– – 2.39% 12
2025
Q2 		$2.58M Hold
1,500,000
– – 1.99% 12
2025
Q1 		$5M Buy
1,500,000
+508,000
+51% +$2.62M 4.28% 5
2024
Q4 		$7.34M Buy
+992,000
New +$9.2M 4.49% 5

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

B Group Inc's IOVA Position: Q2 2026 in Review

B Group Inc held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 1,500,000 shares worth $6.24M. The position accounts for 2.93% of the portfolio, ranked #12.

B Group Inc first reported a position in IOVA in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.34M in Q4 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • B Group Inc held 1,500,000 shares of Iovance Biotherapeutics worth $6.24M as of Q2 2026.
  • B Group Inc left its Iovance Biotherapeutics share count unchanged in Q2 2026.
  • Iovance Biotherapeutics made up 2.93% of B Group Inc's portfolio in Q2 2026, its #12 holding.
  • B Group Inc first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • B Group Inc's Iovance Biotherapeutics position peaked at $7.34M in Q4 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.